...
首页> 外文期刊>Molecular Genetics & Genomic Medicine >DMD Open‐access Variant Explorer (DOVE): A scalable, open‐access, web‐based tool to aid in clinical interpretation of genetic variants in the DMD gene
【24h】

DMD Open‐access Variant Explorer (DOVE): A scalable, open‐access, web‐based tool to aid in clinical interpretation of genetic variants in the DMD gene

机译:DMD开放访问变体资源管理器(DOVE):一种可扩展的,基于Web的开放访问工具,可帮助对DMD基因中的遗传变异进行临床解释

获取原文

摘要

Background Duchenne muscular dystrophy (Duchenne) is caused by pathogenic variants in the DMD gene. Antisense oligonucleotides (AONs) are one emerging precision medicine treatment for Duchenne. DMD molecular genetic testing results guide precision‐therapy molecular eligibility, requiring healthcare providers to perform analyses currently uncommon in clinical laboratory and medical practices. Clear DMD variant notation and interpretation are key components of clinical care with the availability of precision medicine. Methods The DMD Open‐access Variant Explorer (DOVE) is a web‐based aid for DMD variant interpretation which additionally reports variant‐specific predicted molecular eligibility for therapy. DOVE was developed in Python and adapted to the Django Web framework, integrates existing open‐access tools, and does not rely on previous variant report/classification. Results DOVE [ www.dmd.nl/DOVE ] interprets colloquial and HGMD inputs of DMD variants to output HGMD variant nomenclature, theoretical molecular eligibility for therapy, and any predicted deleterious molecular consequences of therapy. DOVE relies on holistic in silico prediction of molecular eligibility for therapy in lieu of reference to an empirically defined, “variant‐eligible” list. Examples illustrate the advantage and necessity for holistic variant interpretation. Conclusion DOVE may prove useful for variant interpretation both at patient‐level and in large‐scale programs such as newborn screening and has broad application in concept to molecular genetic test result interpretation.
机译:背景Duchenne肌营养不良症(Duchenne)是由DMD基因中的致病变异引起的。反义寡核苷酸(AONs)是一种针对杜兴(Duchenne)的新兴精密药物治疗方法。 DMD分子遗传测试结果指导精确治疗分子的资格,要求医疗保健提供者进行临床实验室和医学实践中目前不常见的分析。有了精确医学,清晰的DMD变异符号和解释是临床护理的关键组成部分。方法DMD开放访问变体资源管理器(DOVE)是基于Web的DMD变体解释工具,另外还报告了特定于变体的预测分子治疗资格。 DOVE是使用Python开发的,并且适用于Django Web框架,集成了现有的开放式访问工具,并且不依赖于以前的变体报告/分类。结果DOVE [www.dmd.nl/DOVE]解释DMD变体的口语和HGMD输入,以输出HGMD变体的命名法,理论上适用于治疗的分子以及治疗的任何预期有害分子后果。 DOVE依靠对治疗分子资格的整体计算机模拟来代替根据经验定义的“符合条件的”列表。实例说明了整体变体解释的优点和必要性。结论DOVE可能在患者水平和大规模程序(例如新生儿筛查)中对变体解释都非常有用,并且在概念上广泛应用于分子遗传测试结果的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号